Canada Markets close in 5 hrs 36 mins
  • S&P/TSX

    18,443.52
    -41.01 (-0.22%)
     
  • S&P 500

    3,910.01
    -15.42 (-0.39%)
     
  • DOW

    31,931.14
    -30.72 (-0.10%)
     
  • CAD/USD

    0.8006
    +0.0016 (+0.2057%)
     
  • CRUDE OIL

    62.91
    -0.31 (-0.49%)
     
  • BTC-CAD

    64,063.76
    +1,851.06 (+2.98%)
     
  • CMC Crypto 200

    1,024.16
    +29.50 (+2.97%)
     
  • GOLD FUTURES

    1,772.90
    -25.00 (-1.39%)
     
  • RUSSELL 2000

    2,271.05
    -13.33 (-0.58%)
     
  • 10-Yr Bond

    1.4560
    +0.0670 (+4.82%)
     
  • NASDAQ

    13,515.00
    -82.96 (-0.61%)
     
  • VOLATILITY

    23.18
    +1.84 (+8.62%)
     
  • FTSE

    6,666.22
    +7.25 (+0.11%)
     
  • NIKKEI 225

    30,168.27
    +496.57 (+1.67%)
     
  • CAD/EUR

    0.6542
    -0.0024 (-0.37%)
     

PENUMBRA INVESTOR ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Penumbra To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi LLP
·2 min read

NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Penumbra, Inc. (“Penumbra” or the “Company”) (NYSE:PEN).

If you suffered losses exceeding $50,000 investing in Penumbra stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/PEN or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
877.247.4292
212.983.9330
jwilson@faruqilaw.com

There is no cost or obligation to you.

On November 10, 2020, Quintessential Capital Management issued a research report on Penumbra entitled "Penumbra and its ‘Killer Catheter’: A tale of corporate greed and seemingly blatant disregard for patients’ lives[.]"

Then, on December 8, 2020, Quintessential Capital Management released a follow-up research report entitled "Is Penumbra’s core scientific research authored by a fake person?: The incredible story of Penumbra’s Dr. Antik Bose[.]" The report alleged that some of the Company’s scientific research appear to have been incorrectly credited or even authored by a fake individual.

On the news of the report, Penumbra’s stock price fell $19.95 per share, or 8.91%, to close at $204.07 per share on December 8, 2020.

Then, on December 15, 2020, after the market, Penumbra announced that it was voluntarily "recalling its JET 7 Xtra Flex because the catheter may become susceptible to distal tip damage during use[, which] may result in potential vessel damage, and subsequent patient injury or death."

On this news, Penumbra’s stock price fell $13.84 per share, or 7.33%, to a close of $174.98 per share on December 16, 2020.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.